SCHEMBL3358693

SCHEMBL3358693

C[C@H](NC(=O)[C@H](C)NC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CTSK P43235 4/20 0.62
MME P08473 1/20 0.61
ECE1 P42892 1/20 0.61
CAPN1 P07384 1/20 0.58
CTSL P07711 1/20 0.56
CTSB P07858 1/20 0.56
CTSS P25774 1/20 0.56
CYP1A2 P05177 1/20 0.56
ATM Q13315 1/20 0.56
PLG P00747 1/20 0.54
TPSAB1 Q15661 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22475275 1.00 CTSK (0.62) CTSKMMEECE1CAPN1CTSL
SCHEMBL10954164 1.00 CTSK (0.62) CTSKMMEECE1CAPN1CTSL
SCHEMBL19384712 1.00 CTSK (0.62) CTSKMMEECE1CAPN1CTSL
SCHEMBL8177898 1.00 CTSK (0.62) CTSKMMEECE1CAPN1CTSL
SCHEMBL10954146 1.00 CTSK (0.62) CTSKMMEECE1CAPN1CTSL
SCHEMBL7421757 1.00 CTSK (0.62) CTSKMMEECE1CAPN1CTSL
SCHEMBL8181468 1.00 CTSK (0.62) CTSKMMEECE1CAPN1CTSL
SCHEMBL29453235 1.00 CTSK (0.62) CTSKMMEECE1CAPN1CTSL
Isopropylamine SCHEMBL11518925 0.96 CTSK (0.58) CTSKMMEECE1CAPN1CTSL
SCHEMBL856196 0.94 CTSK (0.61) CTSKMMEECE1CAPN1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279550-B2 Irreversible cysteine protease inhibitors of legumain PROBIODRUG AG (DE) 2007-10-09 US claimed
US-20060178315-A1 Irreversible cysteine protease inhibitors of legumain PROBIODRUG AG 2006-08-10 US claimed
EP-0783489-A1 ALDEHYDE DERIVATIVES AS UPSTEINE PROTEASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 1997-07-16 EP claimed
WO-1996010014-A1 ALDEHYDE DERIVATIVES AS UPSTEINE PROTEASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-04-04 WO claimed
EP-4725560-A2 ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2026-04-15 EP disclosed
EP-4703369-A1 METHOD FOR SYNTHESIZING AMIDE AND/OR POLYPEPTIDE BY USING TEMPORARILY PROTECTED AMINO ACIDS AS AMINE COMPONENTS GUANGZHOU MEDICAL UNIVERSITY (CN) 2026-03-04 EP disclosed
US-20260008808-A1 Method for Synthesizing Amide and/or Polypeptide Using Unprotected Amino Acid as Ammonia Component UNIV GUANGZHOU MEDICAL (CN) 2026-01-08 US disclosed
US-20260001906-A1 Method for Synthesizing Amide and/or Polypeptide Using Temporary Protected Amino Acid as Ammonia Component UNIV GUANGZHOU MEDICAL (CN) 2026-01-01 US disclosed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP disclosed
EP-4574834-A1 METHOD FOR SYNTHESIZING AMIDE AND/OR POLYPEPTIDE WITH UNPROTECTED AMINO ACID AS AMINE COMPONENT GUANGZHOU MEDICAL UNIVERSITY (CN) 2025-06-25 EP disclosed
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-03-27 US disclosed
WO-2024239281-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2024-11-28 WO disclosed
EP-0321722-A2 Process for obtaining dipeptides Degussa Aktiengesellschaft (DE) 1989-06-28 EP disclosed
EP-0234178-A1 New 8-substituted derivatives of an anhydrooctonic acid, methods for their preparation, pharmaceutical preparations containing these and intermediates Astra Läkemedel Aktiebolag (SE) 1987-09-02 EP disclosed
WO-1987003878-A1 NEW 8-SUBSTITUTED DERIVATIVES OF AN ANHYDROOCTONIC ACID, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THESE AND INTERMEDIATES Astra Läkemedel Aktiebolag (SE) 1987-07-02 WO disclosed
EP-0209430-A2 L-di or tripeptides possessing a biological activity for use in human and veterinary medicines, process for their obtention and medicines containing them INSTITUT DE RECHERCHES CHIMIQUES ET BIOLOGIQUES APPLIQUEES (I.R.C.E.B.A.) Société à responsabilité limitée dite: (FR) 1987-01-21 EP disclosed
US-4554100-A ENZYME INHIBITORS SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) 1985-11-19 US disclosed
US-4187216-A ELASTASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 1980-02-05 US disclosed
US-4176116-A ELASTASE ENZYME INHIBITORS HOFFMANN-LA ROCHE INC. (US) 1979-11-27 US disclosed
US-4087520-A Lowering blood pressure with new L-3-(3,4-dihydroxyphenyl)-2-methyl-alanine peptides BOEHRINGER MANNHEIM GMBH (DT) 1978-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008808-A1 Method for Synthesizing Amide and/or Polypeptide Using Unprotected Amino Acid as Ammonia Component ANPEP, PTMS, GCG CTSK 1858/4885MME 277/4885ECE1 1773/4885
US-20060178315-A1 Irreversible cysteine protease inhibitors of legumain LGMN, SERPINB1, SERPINA2 CTSK 28/4885MME 36/4885ECE1 331/4885
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates KIF18B, KIF18A, KIF5B CTSK 2951/4885MME 3629/4885ECE1 3854/4885
US-20260001906-A1 Method for Synthesizing Amide and/or Polypeptide Using Temporary Protected Amino Acid as Ammonia Component BCAT1, BCAT2, PTMS CTSK 2007/4885MME 950/4885ECE1 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.